Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2009-009358-26 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Experimental |
| |
| Arm 2 | Experimental |
| |
| Arm 3 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| F-18 DPA-714 (BAY85-8102) | Drug | Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT |
|
| Measure | Description | Time Frame |
|---|---|---|
| Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by different quantification approaches | Day of Study tracer administration |
| Measure | Description | Time Frame |
|---|---|---|
| Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by visual analysis and standard parameters(e.g. Standardized Uptake Values = SUV) | Day of Study tracer administration | |
| Electrocardiogram (ECG) |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Turku | 20520 | Finland | ||||
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| F-18 DPA-714 (BAY85-8102) | Drug | Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT |
|
| F-18 DPA-714 (BAY85-8102) | Drug | Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood |
|
| At least once within 8 days after treatment |
| Blood pressure | At least 2 times within 8 days after treatment |
| Serum protein | At least once within 8 days after treatment |
| Serum creatinine | At least once within 8 days after treatment |
| Serum GOT (Glutamat-Oxalacetate-Transaminase) | At least once within 8 days after treatment |
| Adverse events collection | Continuously and for a maximum of 28 days after end of observation phase |
| Amsterdam |
| 1081 HV |
| Netherlands |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided